Vaccinex (VCNX) News Today $0.68 0.00 (0.00%) As of 05/23/2025 Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCNX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finanznachrichten.deAbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finance.yahoo.comVaccinex to report new clinical data on pepinemab in enhancing immunotherapyApril 22, 2025 | markets.businessinsider.comVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)April 21, 2025 | globenewswire.comVaccinex director resigns, no disagreement citedMarch 21, 2025 | investing.comVaccinex plans Nasdaq exit as Alzheimer market pressure growsMarch 11, 2025 | finance.yahoo.comVaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 8, 2025 | finanznachrichten.deVaccinex to delist common stock from NasdaqMarch 7, 2025 | markets.businessinsider.comVaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 7, 2025 | globenewswire.comVaccinex receives delisting notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Announces Receipt of Delisting Notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Shares Tumble 63% On Nasdaq DelistingDecember 17, 2024 | marketwatch.comVaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%December 17, 2024 | finance.yahoo.comVaccinex Faces Nasdaq Delisting: What's Going On With The Stock?December 17, 2024 | benzinga.comVaccinex, Inc.: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 19, 2024 | finanznachrichten.deVaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 18, 2024 | globenewswire.comVaccinex provides update on ActivMAb platformNovember 8, 2024 | markets.businessinsider.comVaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITCNovember 7, 2024 | globenewswire.comVaccinex to preset new biomarker data on HNSCCNovember 6, 2024 | markets.businessinsider.comVaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual MeetingNovember 5, 2024 | globenewswire.comVaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemabNovember 1, 2024 | markets.businessinsider.comVaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, SpainOctober 31, 2024 | globenewswire.comVaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD studyOctober 26, 2024 | markets.businessinsider.comWhat's Going On With Vaccinex Stock Wednesday?September 19, 2024 | msn.comVaccinex Announces Exercise of Warrants for $6.2 Million in Gross ProceedsSeptember 18, 2024 | globenewswire.comVCNX Stock Earnings: Vaccinex Reported Results for Q2 2024August 14, 2024 | investorplace.comVaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development PartnershipAugust 14, 2024 | globenewswire.comInsider Buying: Vaccinex, Inc. (NASDAQ:VCNX) Director Purchases 3,653 Shares of StockAugust 8, 2024 | insidertrades.comAlbert Friedberg Acquires 200,000 Shares of Vaccinex, Inc. (NASDAQ:VCNX) StockAugust 2, 2024 | insidertrades.comVaccinex stock tanks 40% despite positive Alzheimer’s study updateJuly 31, 2024 | msn.comVaccinex stock plunges 24% on mixed results for Alzheimer's studyJuly 31, 2024 | msn.comVaccinex, Inc. (VCNX)July 25, 2024 | finance.yahoo.comInvestors Await Key Earnings Reports as US Futures Tread Water in Friday's PremarketJuly 20, 2024 | msn.comInvestors Await Key Earnings Reports as US Futures Tread Water in Friday's PremarketJuly 20, 2024 | msn.comVaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's DiseaseJune 6, 2024 | globenewswire.comVaccinex, Inc.: Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | finanznachrichten.deVCNX Stock Earnings: Vaccinex Reported Results for Q1 2024May 16, 2024 | investorplace.comVaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | globenewswire.comVaccinex faces Nasdaq compliance challengeApril 14, 2024 | investing.comVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023April 2, 2024 | investorplace.comVaccinex Reports 2023 Financial Results and Provides Corporate UpdateApril 2, 2024 | globenewswire.comVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 27, 2024 | globenewswire.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 6, 2024 | investing.comVaccinex Inc VCNXMarch 2, 2024 | morningstar.comVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyFebruary 21, 2024 | finanznachrichten.deVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | markets.businessinsider.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comTrading was temporarily halted for "VCNX" at 07:02 PM with a stated reason of "News pending."February 19, 2024 | marketbeat.comVaccinex Announces 1-For-14 Reverse Stock SplitFebruary 15, 2024 | markets.businessinsider.com Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address VCNX Media Mentions By Week VCNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VCNX News Sentiment▼0.000.75▲Average Medical News Sentiment VCNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VCNX Articles This Week▼00▲VCNX Articles Average Week Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACXP News Today BMRA News Today BCLI News Today PHIO News Today BTAI News Today ADXN News Today SNSE News Today PRTG News Today AIMD News Today SLXN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VCNX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! Save 85% on Weiss Crypto Investor!President Trump just made his first big crypto move … Announcing the creation of a national strategic reser...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
